Centessa (CNTA) | Financial Analysis & Statements
Centessa Pharmaceuticals plc - ADR Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-68.5M
Net Income
-66.2M
Balance Sheet Metrics
Total Assets
687.5M
Total Liabilities
160.6M
Shareholders Equity
526.9M
Debt to Equity
0.30
Cash Flow Metrics
Operating Cash Flow
-62.5M
Free Cash Flow
-55.8M
Revenue & Profitability Trend
Annual Income Flow
2025
Centessa Income Statement From 2020 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Revenue | 15.0M | 0 | 6.9M | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 172.2M | 150.2M | 124.4M | 155.1M | 9.3M |
| Selling, General & Administrative | 50.5M | 50.8M | 53.7M | 55.2M | 1.1M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 222.7M | 201.1M | 178.1M | 210.3M | 10.4M |
| Operating Income | -207.7M | -201.1M | -171.3M | -210.3M | -10.4M |
| Operating Margin % | -1,384.6% | 0.0% | -2,499.4% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | 20.5M | 14.0M | 10.5M | 244.0K | - |
| Interest Expense | 11.5M | 10.1M | 9.9M | 7.3M | 378.0K |
| Other Non-Operating Income | 2.9M | -35.8M | -5.4M | 362.0K | 155.0K |
| Pre-tax Income | -195.7M | -232.9M | -176.1M | -217.0M | -10.7M |
| Income Tax | 1.8M | 2.8M | -25.1M | -747.0K | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -197.5M | -235.8M | -151.1M | -216.2M | -10.7M |
| Net Margin % | -1,316.9% | 0.0% | -2,204.7% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -183.3M | -187.8M | -165.4M | -207.6M | -10.3M |
| EPS (Basic) | - | $-2.06 | $-1.57 | $-2.31 | $-0.15 |
| EPS (Diluted) | - | $-2.06 | $-1.57 | $-2.31 | $-0.15 |
| Basic Shares Outstanding | - | 114473449 | 96177578 | 93400513 | 70890985 |
| Diluted Shares Outstanding | - | 114473449 | 96177578 | 93400513 | 70890985 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Centessa Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 61.3M | 383.2M | 128.0M | 393.6M | 595.1M |
| Short-term Investments | 233.3M | 99.0M | 128.5M | 0 | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 1.8M | 1.8M | 1.6M | 3.3M | 993.0K |
| Total Current Assets | 367.9M | 536.4M | 315.1M | 437.7M | 628.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | - | - |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 26.2M | 28.6M | 32.2M | 5.4M | 699.0K |
| Total Non-Current Assets | 319.6M | 40.4M | 45.2M | 6.6M | 861.0K |
| Total Assets | 687.5M | 576.8M | 360.2M | 444.3M | 629.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 7.6M | 7.1M | 11.8M | 13.8M | 8.1M |
| Short-term Debt | 713.0K | - | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 217.0K | 710.0K | 839.0K | 690.0K | 102.0K |
| Total Current Liabilities | 42.9M | 58.0M | 39.4M | 38.3M | 24.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 117.7M | 117.2M | 84.6M | 69.8M | 75.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 29.0K | 29.0K | 29.0K | - | 37.7M |
| Total Non-Current Liabilities | 117.7M | 117.3M | 84.6M | 69.8M | 113.4M |
| Total Liabilities | 160.6M | 175.3M | 124.0M | 108.1M | 138.1M |
| Equity | |||||
| Common Stock | 405.0K | 359.0K | 273.0K | 265.0K | 252.0K |
| Retained Earnings | -1.2B | -988.7M | -752.9M | -601.9M | -385.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 526.9M | 401.5M | 236.2M | 336.2M | 491.6M |
| Key Metrics | |||||
| Total Debt | 118.4M | 117.2M | 84.6M | 69.8M | 75.7M |
| Working Capital | 324.9M | 478.4M | 275.7M | 399.4M | 604.1M |
Balance Sheet Composition
Centessa Cash Flow Statement From 2020 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -197.5M | -235.8M | -151.1M | -216.2M | -10.7M |
| Depreciation & Amortization | 921.0K | 942.0K | 810.0K | 131.0K | 0 |
| Stock-Based Compensation | 31.0M | 33.5M | 29.4M | 25.0M | 336.0K |
| Working Capital Changes | -7.0M | -10.9M | -16.7M | -5.4M | -1.4M |
| Operating Cash Flow | -168.9M | -209.4M | -164.1M | -199.2M | -11.8M |
| Investing Activities | |||||
| Capital Expenditures | -371.0K | -34.0K | -169.0K | -1.1M | 0 |
| Acquisitions | - | - | - | 0 | 0 |
| Investment Purchases | -739.8M | -140.5M | -264.9M | 0 | - |
| Investment Sales | 321.6M | 171.8M | 138.1M | 0 | - |
| Investing Cash Flow | -418.5M | 31.3M | -127.0M | -931.0K | 0 |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 109.3M | - | 0 | 1.4M |
| Debt Repayment | 0 | -110.1M | - | - | 0 |
| Financing Cash Flow | 270.2M | 353.5M | 20.8M | -261.0K | 1.4M |
| Free Cash Flow | -194.2M | -142.1M | -160.5M | -201.7M | -10.6M |
| Net Change in Cash | -317.3M | 175.4M | -270.3M | -200.3M | -10.4M |
Cash Flow Trend
Centessa Key Financial Ratios
Valuation Ratios
Forward P/E
-20.83
Price to Book
11.18
Price to Sales
406.97
PEG Ratio
-20.83
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-1,384.61%
Return on Equity
-42.55%
Return on Assets
-20.53%
Financial Health
Current Ratio
8.57
Debt to Equity
22.47
Beta
1.26
Per Share Data
EPS (TTM)
$-1.46
Book Value per Share
$3.53
Revenue per Share
$0.11
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CNTA | 6.1B | - | 11.18 | -42.55% | 0.00% | 22.47 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






